Clinical consequences of overdosage with MultiHance have not been reported. Treatment of an overdosage should be directed toward support of vital functions and prompt institution of symptomatic therapy. In a Phase 1 clinical study, doses up to 0.4 mmol/kg were administered to patients. MultiHance has been shown to be dialyzable [see CLINICAL PHARMACOLOGY].
MultiHance is contraindicated in patients with known allergic or hypersensitivity reactions to gadolinium-based contrast agents [see WARNINGS AND PRECAUTIONS].
Last reviewed on RxList: 7/12/2012
This monograph has been modified to include the generic and brand name in many instances.
Additional MultiHance Information
Report Problems to the Food and Drug Administration
Find out what women really need.